Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase

► Vitamin D analog EB1089 decreases gene expression of CYP19A1 in breast cancer cells. ► EB1089 dissociates modulator WSTF from the CYP19A1 promoter in a VDR dependent manner. ► EB1089 reduces the aromatase activity. ► EB1089 is of interest in treatment of endocrine responsive breast cancers. ► WSTF is an interesting drug target for new treatments against breast cancer.